Catalyst Pharmaceutical Partners(CPRX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CPRX Catalyst Pharmaceutical Partners

盘前交易 11-05 05:20:51 EST

21.75

-0.14

-0.64%

最高21.96	最低21.30	成交量74.70万
今开21.82	昨收21.89	日振幅3.02%
总市值25.81亿	流通市值22.28亿	总股本1.19亿
成交额1,623万	换手率0.73%	流通股本1.02亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"CPRX","market":"US","secType":"STK","nameCN":"Catalyst Pharmaceutical Partners","latestPrice":21.75,"timestamp":1730754000000,"preClose":21.89,"halted":0,"volume":747038,"delay":0,"floatShares":102435215,"shares":118687897,"eps":0.580523,"marketStatus":"盘前交易","marketStatusCode":1,"change":-0.14,"latestTime":"11-05 05:20:51 EST","open":21.82,"high":21.96,"low":21.3,"amount":16232638.212692002,"amplitude":0.030151,"askPrice":24.42,"askSize":100,"bidPrice":19.76,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0.580523,"exchange":"NASDAQ","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1730817000000},"adr":0,"listingDate":1162962000000,"adjPreClose":21.75,"adrRate":0,"postHourTrading":{"tag":"盘后","latestPrice":21.74,"preClose":21.75,"latestTime":"19:50 EST","volume":30448,"amount":662218.3008,"timestamp":1730767805133},"volumeRatio":1.0006520635637102,"impliedVol":0.406,"impliedVolPercentile":0.3984},"requestUrl":"/m/hq/s/CPRX","defaultTab":"news","newsList":[{"id":"2460249767","title":"Catalyst Pharmaceuticals, Inc.2024财年第二财季实现净利润40.79百万美元，同比增加8.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2460249767","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460249767?lang=zh_cn&edition=full","pubTime":"2024-08-17 00:00","pubTimestamp":1723824026,"startTime":"0","endTime":"0","summary":"8月17日，Catalyst Pharmaceuticals, Inc.公布财报，公告显示公司2024财年第二财季净利润为40.79百万美元，同比增加8.02%；其中营业收入为1.23亿美元，同比增加23.52%，每股基本收益为0.35美元。机构评级：截至2024年8月17日，当前有7家机构对Catalyst Pharmaceuticals, Inc.目标价做出预测，其中目标均价为30.14美元，其中最低目标价为26.00美元，最高目标价为38.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408170003589f31aed1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408170003589f31aed1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CPRX"],"gpt_icon":0},{"id":"1103700470","title":"异动解读 | Catalyst Pharmaceuticals财报利好 机构看好前景 股价大涨近10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1103700470","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103700470?lang=zh_cn&edition=full","pubTime":"2024-08-09 16:06","pubTimestamp":1723190769,"startTime":"0","endTime":"0","summary":"生物制药公司Catalyst Pharmaceuticals(CPRX.us)今日股价大涨9.98%,报收于17.48美元。公司最新财报数据和机构评级情况或是导致股价大涨的主要原因。\n\nCatalyst Pharmaceuticals最新财报显示,公司实现营业收入98.51百万美元,净利润23.28百万美元,每股收益0.20美元,毛利76.65百万美元。财报数据表现出色,公司业绩持续向好。\n\n此外,机构评级方面,所有7家参与评级的机构均给予该股买入评级,看好公司未来发展前景。公司专注于开发治疗罕见神经肌肉疾病和神经系统疾病的创新疗法,在细分领域具有较强竞争力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"gpt_icon":0},{"id":"2457316479","title":"Catalyst Pharmaceuticals, Inc.盘中异动 股价大涨7.67%报17.48美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2457316479","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457316479?lang=zh_cn&edition=full","pubTime":"2024-08-08 21:32","pubTimestamp":1723123952,"startTime":"0","endTime":"0","summary":"北京时间2024年08月08日21时32分，Catalyst Pharmaceuticals, Inc.股票出现波动，股价快速拉升7.67%。截至发稿，该股报17.48美元/股，成交量4.3186万股，换手率0.04%，振幅1.36%。Catalyst Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为1.16%。其相关个股中，Conduit Pharmaceuticals Inc.、Tevogen Bio Holdings Inc C/Wts 14/02/2029 、Anew Medical, Inc.涨幅较大，Anew Medical, Inc.、Conduit Pharmaceuticals Inc.、Aditxt, Inc.较为活跃，换手率分别为179.48%、174.46%、39.51%，振幅较大的相关个股有Conduit Pharmaceuticals Inc.、Anew Medical, Inc.、Generation Bio Co.，振幅分别为25.33%、15.60%、13.96%。Catalyst Pharmaceuticals, Inc.公司简介：Catalyst Pharmaceuticals Inc是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408082132329f1aa453&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408082132329f1aa453&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CPRX","BK4139"],"gpt_icon":0},{"id":"2457056077","title":"Catalyst Pharmaceuticals Inc   预计每股收益 26 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2457056077","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457056077?lang=zh_cn&edition=full","pubTime":"2024-08-06 10:59","pubTimestamp":1722913183,"startTime":"0","endTime":"0","summary":"   * Catalyst Pharmaceuticals Inc    将于8月7日公布截至2024年6月30日的财报，预计该公司的季度收入将有所增长。)   * LSEG 分析师对 Catalyst Pharmaceuticals Inc 的平均预期为每股收益 26 美分。* 华尔街对 Catalyst Pharmaceuticals Inc 的 12 个月目标价中位数为 26.00 美元，高于其上次收盘价 15.49 美元。8月6日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。(如对本报告中的数据有任何疑问，请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Catalyst Pharmaceuticals Inc   预计每股收益 26 美分 - 财报前瞻","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"gpt_icon":0},{"id":"2450367051","title":"Catalyst Pharmaceuticals, Inc.盘中异动 股价大涨5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2450367051","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2450367051?lang=zh_cn&edition=full","pubTime":"2024-07-11 23:33","pubTimestamp":1720711999,"startTime":"0","endTime":"0","summary":"北京时间2024年07月11日23时33分，Catalyst Pharmaceuticals, Inc.股票出现波动，股价急速上涨5.05%。Catalyst Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.59%。Catalyst Pharmaceuticals, Inc.公司简介：Catalyst Pharmaceuticals Inc是一家生物制药公司。消息层面，截至23时33分，《美银证券维持Catalyst Pharmaceuticals买入评级》资讯为影响Catalyst Pharmaceuticals, Inc.的重要信息。该信息摘要如下：美银证券分析师Jason Gerberry维持$Catalyst Pharmaceuticals $买入评级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407112333199681c0ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407112333199681c0ef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CPRX","BK4139"],"gpt_icon":0},{"id":"2443278296","title":"Catalyst Pharmaceuticals Inc   预计每股收益 26 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2443278296","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2443278296?lang=zh_cn&edition=full","pubTime":"2024-06-14 21:02","pubTimestamp":1718370139,"startTime":"0","endTime":"0","summary":"   * Catalyst Pharmaceuticals Inc    将于6月17日公布截至2024年6月30日的季度业绩(估计)，预计该公司的季度收入将出现增长。)   * LSEG 分析师对 Catalyst Pharmaceuticals Inc 的平均预期为每股收益 26 美分。* 华尔街对 Catalyst Pharmaceuticals Inc 的 12 个月目标价中位数为 26.00 美元，高于其上次收盘价 15.33 美元。6月14日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。(如对本报告中的数据有任何疑问，请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"gpt_icon":0},{"id":"2441068672","title":"Catalyst Pharmaceuticals Inc   预计每股收益 26 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2441068672","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2441068672?lang=zh_cn&edition=full","pubTime":"2024-06-07 20:35","pubTimestamp":1717763712,"startTime":"0","endTime":"0","summary":"   * Catalyst Pharmaceuticals Inc    预计将在 6 月 10 日公布的截至 0001 年 1 月 1 日的业绩报告(估计) 中显示出季度收入的增长。)   * LSEG 分析师对 Catalyst Pharmaceuticals Inc 的平均预期为每股收益 26 美分。* 华尔街对 Catalyst Pharmaceuticals Inc 的 12 个月目标价中位数为 26.00 美元，高于其上次收盘价 15.76 美元。6月7日 - 上一季度业绩。除非另有说明，所有数字均以美元为单位。(如对本报告中的数据有任何疑问，请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"gpt_icon":0},{"id":"2441743421","title":"奥本海默：重申Catalyst Pharmaceuticals(CPRX.US)评级由优于大市调整至优于大市评级, 目标价由29.","url":"https://stock-news.laohu8.com/highlight/detail?id=2441743421","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2441743421?lang=zh_cn&edition=full","pubTime":"2024-06-06 22:31","pubTimestamp":1717684278,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CPRX","BK4139"],"gpt_icon":0},{"id":"2440247463","title":"HC Wainwright &amp; Co.：重申Catalyst Pharmaceuticals(CPRX.US)评级，由买入调整至买入评级, 目标价由26.","url":"https://stock-news.laohu8.com/highlight/detail?id=2440247463","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2440247463?lang=zh_cn&edition=full","pubTime":"2024-06-03 18:27","pubTimestamp":1717410474,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CPRX","BK4139"],"gpt_icon":0},{"id":"2438371324","title":"Catalyst Pharmaceuticals Inc   预计每股收益 26 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2438371324","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2438371324?lang=zh_cn&edition=full","pubTime":"2024-05-28 21:01","pubTimestamp":1716901273,"startTime":"0","endTime":"0","summary":"   * Catalyst Pharmaceuticals Inc    预计在5月30日公布的截至2024年6月30日的业绩报告中将显示季度收入增长(预计)    * 根据7位分析师基于LSEG数据的平均估计，这家总部位于佛罗里达州科勒尔盖布尔斯的公司的营收预计将从去年同期的9958万美元增长12.4%，达到1.1196亿美元。)   * LSEG 分析师对 Catalyst Pharmaceuticals Inc 的平均预期为每股收益 26 美分。* 华尔街对 Catalyst Pharmaceuticals Inc 的 12 个月目标价中位数为 26.00 美元，高于其上次收盘价 15.87 美元。5月28日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"gpt_icon":0},{"id":"2436154945","title":"Catalyst Pharmaceuticals, Inc.2024财年第一财季实现净利润23.28百万美元，同比减少21.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2436154945","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2436154945?lang=zh_cn&edition=full","pubTime":"2024-05-18 00:15","pubTimestamp":1715962545,"startTime":"0","endTime":"0","summary":"3月31日，Catalyst Pharmaceuticals, Inc.公布财报，公告显示公司2024财年第一财季净利润为23.28百万美元，同比减少21.27%；其中营业收入为98.51百万美元，同比增加15.39%，每股基本收益为0.20美元。机构评级：截至2024年3月31日，当前有7家机构对Catalyst Pharmaceuticals, Inc.目标价做出预测，其中目标均价为27.29美元，其中最低目标价为24.00美元，最高目标价为34.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051800155887750692&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051800155887750692&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CPRX"],"gpt_icon":0},{"id":"2434787853","title":"HC Wainwright & Co.：维持Catalyst Pharmaceuticals(CPRX.US)评级，由买入调整至买入评级, 目标价由24.00美元调整至26.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2434787853","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2434787853?lang=zh_cn&edition=full","pubTime":"2024-05-10 20:25","pubTimestamp":1715343927,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：维持Catalyst Pharmaceuticals(CPRX.US)评级，由买入调整至买入评级, 目标价由24.00美元调整至26.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405102025308750c3ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405102025308750c3ff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CPRX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.catalystpharma.com","stockEarnings":[{"period":"1week","weight":-0.005},{"period":"1month","weight":0.0875},{"period":"3month","weight":0.3434},{"period":"6month","weight":0.4776},{"period":"1year","weight":0.6527},{"period":"ytd","weight":0.2939}],"compareEarnings":[{"period":"1week","weight":-0.019},{"period":"1month","weight":-0.0055},{"period":"3month","weight":0.0913},{"period":"6month","weight":0.1017},{"period":"1year","weight":0.3108},{"period":"ytd","weight":0.1988}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Catalyst Pharmaceuticals, Inc.于2006年7月在特拉华州注册成立。该公司是一家商业阶段、以患者为中心的生物制药公司，专注于为患有罕见和难以治疗的疾病的患者提供新的高质量药物的许可、开发和商业化。该公司利用协调一致的勤奋努力，寻找能够改善那些患有罕见或难以治疗的疾病的人的生活的疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.053866},{"month":2,"riseRate":0.666667,"avgChangeRate":-0.012194},{"month":3,"riseRate":0.666667,"avgChangeRate":0.104304},{"month":4,"riseRate":0.388889,"avgChangeRate":0.036621},{"month":5,"riseRate":0.555556,"avgChangeRate":-0.032711},{"month":6,"riseRate":0.555556,"avgChangeRate":0.04776},{"month":7,"riseRate":0.611111,"avgChangeRate":0.118672},{"month":8,"riseRate":0.666667,"avgChangeRate":0.234994},{"month":9,"riseRate":0.388889,"avgChangeRate":-0.026925},{"month":10,"riseRate":0.444444,"avgChangeRate":-0.055859},{"month":11,"riseRate":0.5,"avgChangeRate":0.009691},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.030132}],"exchange":"NASDAQ","name":"Catalyst Pharmaceutical Partners","nameEN":"Catalyst Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Catalyst Pharmaceutical Partners(CPRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Catalyst Pharmaceutical Partners(CPRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Catalyst Pharmaceutical Partners,CPRX,Catalyst Pharmaceutical Partners股票,Catalyst Pharmaceutical Partners股票老虎,Catalyst Pharmaceutical Partners股票老虎国际,Catalyst Pharmaceutical Partners行情,Catalyst Pharmaceutical Partners股票行情,Catalyst Pharmaceutical Partners股价,Catalyst Pharmaceutical Partners股市,Catalyst Pharmaceutical Partners股票价格,Catalyst Pharmaceutical Partners股票交易,Catalyst Pharmaceutical Partners股票购买,Catalyst Pharmaceutical Partners股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Catalyst Pharmaceutical Partners(CPRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Catalyst Pharmaceutical Partners(CPRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}